Ralf G.
- Country
- Germany
- Department
- Department of Dermatology, Venereology, Allergology and Phlebology
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Phase 3 Randomized Controlled Trial of Adjuvant mRNA-4157 and Pembrolizumab Versus Placebo and Pembrolizumab in High-Risk Stage II-IV Melanoma
Data & Insights
Has run more than one trial at 149 of 268 partner sites.
Specializations
Melanoma Research
This investigator specializes in treating various forms of melanoma, with particular focus on advanced and metastatic cases. Their research encompasses both resectable and unresectable melanoma, including specific mutations like BRAF V600E/K and NRAS.
- Advanced Stage Melanoma Treatment
- Post-Resection Therapy
- Mutation-Specific Approaches
Their work extends to novel combination therapies and immunotherapy applications in melanoma treatment.
Immunotherapy Innovation
The investigator focuses on advancing immunotherapy treatments, particularly studying novel combinations with established therapies. Their research includes evaluation of bispecific T cell-engaging molecules and various immunotherapeutic approaches.
- Combination Immunotherapy
- Novel Therapeutic Compounds
- Treatment Response Assessment
A significant portion of their work involves investigating new immunotherapy delivery methods and combinations.
Skin Cancer Treatment
The investigator's expertise extends to various forms of skin cancer, including specialized research in basal cell carcinoma and advanced cutaneous malignancies. Their work encompasses both adult and pediatric populations.
- Advanced Skin Cancer Therapies
- First-line Treatment Strategies
- Targeted Therapeutic Approaches
Research includes evaluation of novel therapeutic compounds and treatment combinations for various skin cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.